CN109674903A - One curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent - Google Patents
One curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent Download PDFInfo
- Publication number
- CN109674903A CN109674903A CN201910087886.0A CN201910087886A CN109674903A CN 109674903 A CN109674903 A CN 109674903A CN 201910087886 A CN201910087886 A CN 201910087886A CN 109674903 A CN109674903 A CN 109674903A
- Authority
- CN
- China
- Prior art keywords
- parts
- hpv
- raw material
- therapeutic agent
- cervical polyp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention proposes a curing hysteromyomas, uterus adenomyosis, cervical polyp, the therapeutic agent of HPV, including consisting of ingredient: 10~20 parts of broomrape, 5~10 parts of ganoderma lucidum, 5~10 parts of alum, 5~10 parts of wild ginseng, 10~20 parts of peach kernel, 10~20 parts of safflower, 10~20 parts of motherwort, 10~15 parts of borneol, 5~10 parts of kuh-seng, the drug is to staphylococcus aureus, Escherichia coli, Candida albicans, HPV viruse has inhibiting effect, it can be in fibroid, uterus adenomyosis, cervical polyp, bacteriostasis antibiosis is used in the therapeutic process of HPV, clear up the daily antibacterial nursing of gynaecology's rubbish；The invention also provides a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent process flow, easy to operate including picking of raw material, pretreatment of raw material, drying, crushing, bag making, packaging and storage, required material is simple and easy to get, cost is relatively low, is worthy to be popularized.
Description
Technical field
The present invention relates to gyniatrics technical field of pharmaceuticals, a specially curing hysteromyoma, uterus adenomyosis, uterine neck breaths
The therapeutic agent of meat, HPV.
Background technique
Fibroid be in female sex organ in one of the most common type benign tumour and human body the most common tumour it
One, also known as fibromyoma, fibroma uteri.Since fibroid is mainly formed by Uterine Smooth Cell hyperplasia, wherein
There is a small amount of fibrous connective tissue to exist as a kind of supporting tissue, therefore referred to as leiomyoma of uterus is more definite, abbreviation uterus
Myomata.
Adenomyosis is endometrial gland and interstitial intrusion mesometrium formation is diffused or the lesion of limitation, with son
Endometriosis is the same, belongs to common gynecological disease and difficult disease.Adenomyosis mostly occur in 30~50 years old or so through producing
Woman, but also seen in the women that youth is not given birth to, this may perform the operation to increase with various uteroventral operations certain relationship.About 15%
Patient merges endometriosis, and about 50% merges fibroid.The treatment of this disease can use pharmaceutical intervention, and also operable is controlled
It treats, but radical cure is more difficult, only patient's post menopausal uterus adenomyosis gradually can voluntarily be alleviated.So the choosing of clinical treatment
It selects, need to require to carry out individuation selection in conjunction with the age of patient, symptom and fertility.
Cervical polyp (cervical polyp) is one kind of chronic cervicitis performance, more common in married woman.
Due to chronic inflammation long-time stimulus, make cervical canal part mucous membrane hyperplasia, excludes foreign matter tendency because uterus has, the mucous membrane of hyperplasia can be made
It is gradually prominent from basal part to cervical orifice and form polyp.Cervical polyp is divided into two kinds, a kind of breath from cervical mucosal
Meat separately has a kind of polyp from cervicovaginal part.Polyp can single-shot or multiple, differ in size, diameter mostly in 1cm hereinafter,
Biggish polyp is likely to occur certain clinical symptoms, and lesser polyp can only be sent out in gynecologial examination without any symptom
It is existing.Cervical polyp has a possibility that canceration (less than 1%), once make a definite diagnosis should row polyp enucleation, sample send pathologic finding.
Human papilloma virus (HPV) is a kind of papilloma vacuolating virus A category for belonging to papovaviridae, is spherical DNA
Virus can cause the scaly epithelium of human skin mucous membrane to be proliferated.Show as the symptoms such as verruca vulgaris, genital wart (condyloma acuminatum).
As the disease incidence of condyloma acuminatum in venereal disease rapidly rises and cervical carcinoma, cancer of anus etc. increase, human papilloma virus infection is got over
More to cause the concern of people.
Summary of the invention
The technical problem to be solved by the present invention is to overcome the existing defects, provides a curing hysteromyoma, uterus adenomyosis, palace
The therapeutic agent of neck polyp, HPV can effectively solve the problems in background technique.
To achieve the above object, the invention provides the following technical scheme: a curing hysteromyoma, uterus adenomyosis, uterine neck breath
The therapeutic agent of meat, HPV, including consisting of ingredient: 10~20 parts of broomrape, 5~10 parts of ganoderma lucidum, 5~10 parts of alum, wild ginseng
5~10 parts, 10~20 parts of peach kernel, 10~20 parts of safflower, 10~20 parts of motherwort, 10~15 parts of borneol, 5~10 parts of kuh-seng.
As a preferred technical solution of the present invention, a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV are controlled
Treat drug, including following parts by weight constituent: 12~18 parts of broomrape, 7~8 parts of ganoderma lucidum, 7~8 parts of alum, wild ginseng 7~8
Part, 7~8 parts of peach kernel, 12~18 parts of safflower, 12~18 parts of motherwort, 11~14 parts of borneol, 7~8 parts of kuh-seng.
As a preferred technical solution of the present invention, a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV are controlled
Treat drug, including following parts by weight constituent: 20 parts of broomrape, 10 parts of ganoderma lucidum, 10 parts of alum, 10 parts of wild ginseng, 20 parts of peach kernel,
20 parts of safflower, 20 parts of motherwort, 15 parts of borneol, 10 parts of kuh-seng.
As a preferred technical solution of the present invention, a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV are controlled
Treat drug, including following parts by weight constituent: 10 parts of broomrape, 5 parts of ganoderma lucidum, 5 parts of alum, 5 parts of wild ginseng, 10 parts of peach kernel, hiding
10 parts of safflower, 10 parts of motherwort, 10 parts of borneol, 5 parts of kuh-seng.
The invention also provides a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent technique stream
Journey, comprising the following steps:
S1. picking of raw material: the constituent of selected above-mentioned each parts by weight is as raw material；
S2. pretreatment of raw material: cleaning the raw material in step S1, dedusting impurity elimination；
S3. it dries: pretreated raw material in step S2 is dried；
S4. crush: the raw material after will be dry in step S3, which is knocked down in ultrafine crusher, to be crushed, after crushing by raw material powder into
Row is uniformly mixed, and obtains drug powder；
S5. bag making: simple medicine bag is made using suitable sterilized non-fat gauze, is often packaged into drug obtained in step S4
Powder is fastened with cotton thread and reserves 12 centimeter length draught lines to take out pack；
S6. it packs: being packed by this product packing specification requirement, and be put into 1 specification, cover box cover, seal mouth label, by packet
The packaging of dress instruction specification is cased, and area to be checked is put into after filling；
S7. store in a warehouse: for storage after sampling observation is qualified, the quality certification is filled in granting, (name of an article, lot number, specification, scrutineer, check day
Phase and packaging) it is put into a quality certification, with adhesive tape for sealing boxes, then stored after being packaged with baling press.
As a preferred technical solution of the present invention, in the step S5 bag making process, the drug powder being often packaged into has
Five grams and seven grams of two kinds of specifications.
Compared with prior art, the invention proposes the treatments of a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV
Drug has inhibiting effect to staphylococcus aureus, Escherichia coli, Candida albicans, HPV viruse, can be in fibroid, uterus
Gland flesh disease, cervical polyp, HPV therapeutic process in for bacteriostasis antibiosis, cleaning the daily antibacterial nursing of gynaecology's rubbish；The present invention is also
Propose a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent process flow, it is easy to operate, it is required
Material is simple and easy to get, and cost is relatively low, is worthy to be popularized.
Specific embodiment
Combined with specific embodiments below the present invention is made further to explain, it is clear that described embodiment is only this hair
Bright a part of the embodiment, instead of all the embodiments.Based on the embodiments of the present invention, those of ordinary skill in the art are not having
Every other embodiment obtained under the premise of creative work is made, shall fall within the protection scope of the present invention.
Embodiment one
The present invention provides the therapeutic agent of a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV, including consisting of
Ingredient: 15 parts of broomrape, 8 parts of ganoderma lucidum, 8 parts of alum, 8 parts of wild ginseng, 8 parts of peach kernel, 15 parts of safflower, 15 parts of motherwort, borneol 13
Part, 8 parts of kuh-seng.
Its process flow, comprising the following steps:
S1. picking of raw material: the constituent of selected above-mentioned each parts by weight is as raw material；
S2. pretreatment of raw material: cleaning the raw material in step S1, dedusting impurity elimination；
S3. it dries: pretreated raw material in step S2 is dried；
S4. crush: the raw material after will be dry in step S3, which is knocked down in ultrafine crusher, to be crushed, after crushing by raw material powder into
Row is uniformly mixed, and obtains drug powder；
S5. bag making: simple medicine bag is made using suitable sterilized non-fat gauze, is often packaged into drug obtained in step S4
Powder, the drug powder being often packaged into have five grams and seven grams of two kinds of specifications, are fastened with cotton thread and reserve 12 centimeter length draught lines to take
Pack out；
S6. it packs: being packed by this product packing specification requirement, and be put into 1 specification, cover box cover, seal mouth label, by packet
The packaging of dress instruction specification is cased, and area to be checked is put into after filling；
S7. store in a warehouse: for storage after sampling observation is qualified, the quality certification is filled in granting, (name of an article, lot number, specification, scrutineer, check day
Phase and packaging) it is put into a quality certification, with adhesive tape for sealing boxes, then stored after being packaged with baling press.
Embodiment two
The present invention provides the therapeutic agent of a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV, including consisting of
Ingredient: 20 parts of broomrape, 10 parts of ganoderma lucidum, 10 parts of alum, 10 parts of wild ginseng, 20 parts of peach kernel, 20 parts of safflower, 20 parts of motherwort, ice
15 parts of piece, 10 parts of kuh-seng.
Its process flow, comprising the following steps:
S1. picking of raw material: the constituent of selected above-mentioned each parts by weight is as raw material；
S2. pretreatment of raw material: cleaning the raw material in step S1, dedusting impurity elimination；
S3. it dries: pretreated raw material in step S2 is dried；
S4. crush: the raw material after will be dry in step S3, which is knocked down in ultrafine crusher, to be crushed, after crushing by raw material powder into
Row is uniformly mixed, and obtains drug powder；
S5. bag making: simple medicine bag is made using suitable sterilized non-fat gauze, is often packaged into drug obtained in step S4
Powder, the drug powder being often packaged into have five grams and seven grams of two kinds of specifications, are fastened with cotton thread and reserve 12 centimeter length draught lines to take
Pack out；
S6. it packs: being packed by this product packing specification requirement, and be put into 1 specification, cover box cover, seal mouth label, by packet
The packaging of dress instruction specification is cased, and area to be checked is put into after filling；
S7. store in a warehouse: for storage after sampling observation is qualified, the quality certification is filled in granting, (name of an article, lot number, specification, scrutineer, check day
Phase and packaging) it is put into a quality certification, with adhesive tape for sealing boxes, then stored after being packaged with baling press.
Embodiment three
The present invention provides the therapeutic agent of a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV, including consisting of
Ingredient: 10 parts of broomrape, 5 parts of ganoderma lucidum, 5 parts of alum, 5 parts of wild ginseng, 10 parts of peach kernel, 10 parts of safflower, 10 parts of motherwort, borneol 10
Part, 5 parts of kuh-seng.
Its process flow, comprising the following steps:
S1. picking of raw material: the constituent of selected above-mentioned each parts by weight is as raw material；
S2. pretreatment of raw material: cleaning the raw material in step S1, dedusting impurity elimination；
S3. it dries: pretreated raw material in step S2 is dried；
S4. crush: the raw material after will be dry in step S3, which is knocked down in ultrafine crusher, to be crushed, after crushing by raw material powder into
Row is uniformly mixed, and obtains drug powder；
S5. bag making: simple medicine bag is made using suitable sterilized non-fat gauze, is often packaged into drug obtained in step S4
Powder, the drug powder being often packaged into have five grams and seven grams of two kinds of specifications, are fastened with cotton thread and reserve 12 centimeter length draught lines to take
Pack out；
S6. it packs: being packed by this product packing specification requirement, and be put into 1 specification, cover box cover, seal mouth label, by packet
The packaging of dress instruction specification is cased, and area to be checked is put into after filling；
S7. store in a warehouse: for storage after sampling observation is qualified, the quality certification is filled in granting, (name of an article, lot number, specification, scrutineer, check day
Phase and packaging) it is put into a quality certification, with adhesive tape for sealing boxes, then stored after being packaged with baling press.
The invention proposes a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent, which makes
With method are as follows: vulva is cleaned at night, and one is contracted for fixed output quotas product merging intravaginal, deep about 10~12 centimetres, the end of a thread is stayed in external genital, and 5 grams
It wraps every packet to retain in vivo 5~7 days, the every packet of 7 grams of packets retains 8~12 days in vivo, and when taking-up only need to gently pull out cotton thread, wash
Only；9 packets are as a treatment course；One course for the treatment of of less serious case, severe one need 2 courses for the treatment of, 95% or more cure rate；The points for attention of the drug are such as
Under: 1, this product cannot substitute drug or medical instrument, and 2, with pack go out meat slag specimen or mucous membrane sample category normal phenomenon when taking out, 3, not
The women that weds and pregnant woman, glycosuria people disabling.The drug has staphylococcus aureus, Escherichia coli, Candida albicans, HPV viruse
Inhibiting effect, can fibroid, uterus adenomyosis, cervical polyp, HPV therapeutic process in for bacteriostasis antibiosis, cleaning woman
The daily antibacterial nursing of section's rubbish；The invention also provides a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV medicine
The process flow of object, easy to operate, required material is simple and easy to get, and cost is relatively low, is worthy to be popularized.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (6)
1. the therapeutic agent of a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV, which is characterized in that including following weight
Part constituent: 10~20 parts of broomrape, 5~10 parts of ganoderma lucidum, 5~10 parts of alum, 5~10 parts of wild ginseng, 10~20 parts of peach kernel, hiding
10~20 parts of safflower, 10~20 parts of motherwort, 10~15 parts of borneol, 5~10 parts of kuh-seng.
2. the therapeutic agent of a curing hysteromyoma according to claim 1, uterus adenomyosis, cervical polyp, HPV, special
Sign is, including following parts by weight constituent: 12~18 parts of broomrape, 7~8 parts of ganoderma lucidum, 7~8 parts of alum, wild ginseng 7~8
Part, 7~8 parts of peach kernel, 12~18 parts of safflower, 12~18 parts of motherwort, 11~14 parts of borneol, 7~8 parts of kuh-seng.
3. the therapeutic agent of a curing hysteromyoma according to claim 1, uterus adenomyosis, cervical polyp, HPV, special
Sign is, including following parts by weight constituent: 20 parts of broomrape, 10 parts of ganoderma lucidum, 10 parts of alum, 10 parts of wild ginseng, 20 parts of peach kernel,
20 parts of safflower, 20 parts of motherwort, 15 parts of borneol, 10 parts of kuh-seng.
4. the therapeutic agent of a curing hysteromyoma according to claim 1, uterus adenomyosis, cervical polyp, HPV, special
Sign is, including following parts by weight constituent: 10 parts of broomrape, 5 parts of ganoderma lucidum, 5 parts of alum, 5 parts of wild ginseng, 10 parts of peach kernel, hiding
10 parts of safflower, 10 parts of motherwort, 10 parts of borneol, 5 parts of kuh-seng.
5. the process flow of the therapeutic agent of a curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV, it is characterised in that: packet
Include following steps:
S1. picking of raw material: the constituent of selected above-mentioned each parts by weight is as raw material；
S2. pretreatment of raw material: cleaning the raw material in step S1, dedusting impurity elimination；
S3. it dries: pretreated raw material in step S2 is dried；
S4. crush: the raw material after will be dry in step S3, which is knocked down in ultrafine crusher, to be crushed, and mixes raw material powder after crushing
It closes uniformly, obtains drug powder；
S5. bag making: being made simple medicine bag using suitable sterilized non-fat gauze, be often packaged into drug powder obtained in step S4,
It is fastened with cotton thread and reserves 12 centimeter length draught lines to take out pack；
S6. it packs: being packed by this product packing specification requirement, and be put into 1 specification, cover box cover, seal mouth label, refer to by packaging
It enables the packaging of specification case, area to be checked is put into after filling；
S7. store in a warehouse: for storage after sampling observation is qualified, the quality certification is filled in granting, (name of an article, lot number, specification, scrutineer, check data and
Packaging) it is put into a quality certification, with adhesive tape for sealing boxes, then stored after being packaged with baling press.
6. the technique of the therapeutic agent of a curing hysteromyoma according to claim 5, uterus adenomyosis, cervical polyp, HPV
Process, which is characterized in that in the step S5 bag making process, the drug powder being often packaged into has five grams and seven grams of two kinds of specifications.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910087886.0A CN109674903A (en) | 2019-01-29 | 2019-01-29 | One curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910087886.0A CN109674903A (en) | 2019-01-29 | 2019-01-29 | One curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109674903A true CN109674903A (en) | 2019-04-26 |
Family
ID=66195072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910087886.0A Pending CN109674903A (en) | 2019-01-29 | 2019-01-29 | One curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109674903A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110201150A (en) * | 2019-07-12 | 2019-09-06 | 广州莎蔓生物科技有限公司 | A kind of drug increasing the anti-HPV of human body cell activity |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1151878A (en) * | 1995-12-13 | 1997-06-18 | 韩贵民 | Prepn of Chinese medicine for gynopathy |
| CN105362383A (en) * | 2015-12-16 | 2016-03-02 | 郑州郑先医药科技有限公司 | Traditional Chinese medicine effervescent tablets for treating gynecologic inflammations and preparation method thereof |
| CN106177007A (en) * | 2016-08-16 | 2016-12-07 | 华中科技大学同济医学院附属同济医院 | A kind of Chinese medicine suppository of cervical disease for treating high-risk HPV persistent infection and preparation method thereof |
-
2019
- 2019-01-29 CN CN201910087886.0A patent/CN109674903A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1151878A (en) * | 1995-12-13 | 1997-06-18 | 韩贵民 | Prepn of Chinese medicine for gynopathy |
| CN105362383A (en) * | 2015-12-16 | 2016-03-02 | 郑州郑先医药科技有限公司 | Traditional Chinese medicine effervescent tablets for treating gynecologic inflammations and preparation method thereof |
| CN106177007A (en) * | 2016-08-16 | 2016-12-07 | 华中科技大学同济医学院附属同济医院 | A kind of Chinese medicine suppository of cervical disease for treating high-risk HPV persistent infection and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 侯萌，等: "宫颈炎康栓治疗宫颈高危型人乳头瘤病毒感染疗效观察", 《中国实用妇科与产科杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110201150A (en) * | 2019-07-12 | 2019-09-06 | 广州莎蔓生物科技有限公司 | A kind of drug increasing the anti-HPV of human body cell activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107744417B (en) | One kind can post-operation adhesion preventing instrument in degradable uterine cavity | |
| CN104224923A (en) | Tea tree essential oil antimicrobial gel for treating vaginal disease in gynecology | |
| CN105078642B (en) | A kind of uterus implant | |
| CN102145073B (en) | Pharmaceutical composition for treating gynecological inflammation and preparation method thereof | |
| CN102144988A (en) | Chitosan cervix uteri anti-microbial membrane and preparation method thereof | |
| CN109674903A (en) | One curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent | |
| CN102274424A (en) | Chinese medicinal patch pad for noninvasive detoxifying in reproductive system and production method thereof | |
| RO131947A2 (en) | Stabilized solution based on active ingredients and method for preparing the stabilized solution of active ingredients | |
| CN102727677A (en) | Novel compound donkey-hide glue extract powder formula, preparation and application of novel compound donkey-hide glue extract powder formula | |
| CN102988543B (en) | Traditional Chinese medicine for treating hyperplasia of mammary glands and preparation method of traditional Chinese medicine | |
| CN106540046A (en) | A kind of vagina antibiosis pharmaceutical gel | |
| CN201618299U (en) | Intrauterine medicine slow-release device | |
| French et al. | The frequency of Candida infections in pregnancy and their treatment with clotrimazole | |
| CN113855689B (en) | Application of engeletin or isomer thereof in preparation of medicine for treating endometriosis | |
| CN108852569A (en) | A kind of degradable support diaphragm apparatus for preventing and treating Asherman's syndrom | |
| CN104548050A (en) | Composition as well as preparation method and application thereof | |
| CN108498705A (en) | Vagina doubts glue bolt and preparation method thereof | |
| CN104606212B (en) | Difunctional vagina compound temperature-sensitive hydrogel preparation of microorganism and preparation method thereof is practised contraception and killed to one kind | |
| CN106821585A (en) | Novel contraceptive medical instrument | |
| CN104840531A (en) | Postoperative external smear used after gynecologic surgeries | |
| CN1857459A (en) | Capsule for treating women's inflammation | |
| CN109730962A (en) | A kind of suppository and preparation method thereof for treating gynaecological imflammation | |
| CN107837274A (en) | A kind of purposes of diet fiber composition | |
| CN103536706B (en) | A kind of Chinese medicine for the treatment of trimester of pregnancy monilial vaginitis smokes lotion | |
| CN102614341B (en) | Chinese medicinal composition for promoting fracture healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190426 |
|
| RJ01 | Rejection of invention patent application after publication |